Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00086500" target="_blank" >RIV/00216224:14110/15:00086500 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/15:00063951 RIV/00843989:_____/15:E0104671
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1500857" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1500857</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1500857" target="_blank" >10.1056/NEJMoa1500857</a>

Result language
angličtina
Original language name
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Original language description
BACKGROUND The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y(12) receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS We randomly assigned, in a double-blind 1: 1: 1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mgtwice daily, or placebo. All the patients were to receive low-dose aspirin and were followed for a median of 33 months. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. RESULTS The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)